AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Kala Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call

May 2, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--May 2, 2019--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 2881526. To access a live webcast and subsequent archived recording of the call, please visit the “Investors & Media” section on the Kala website at http://kalarx.com /.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYS™ for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a New Drug Application (NDA) has been filed with the United States Food and Drug Administration (FDA) and a target action date under the Prescription Drug User Fee Act (PDUFA) has been set for August 15, 2019.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005012/en/

CONTACT: Investors:

Michael Schaffzin, 212-362-1200

michael@sternir.com

or

Media:

Kari Watson, 781-235-3060

kwatson@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH OPTICAL PHARMACEUTICAL PROFESSIONAL SERVICES FINANCE RESEARCH SCIENCE

SOURCE: Kala Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 05/02/2019 08:00 AM/DISC: 05/02/2019 08:01 AM

http://www.businesswire.com/news/home/20190502005012/en

All contents © copyright 2019 The Associated Press.All rights reserved.